Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CONV 01-alpha + PSMA I&T

Next Previous
X
Search
Drug Profile

CONV 01-alpha + PSMA I&T

Latest Information Update: 31 Oct 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Convergent Therapeutics
  • Class Antineoplastics; Diagnostic agents; Drug conjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 23 Oct 2022 Radiopharm Theranostics and NorthStar Medical Radioisotopes enters into a clinical supply agreement for the supplyof Radiopharm Theranostics with Actinium-225
  • 01 Feb 2021 Preclinical trials in Prostate cancer (Diagnosis) in USA (Parenteral)
  • 01 Feb 2021 Convergent Therapeutics plans a phase Ib/IIa (Combination therapy, with both alpha emitters) in Prostate cancer in February 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top